Catalog No.
PHJ40401
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human SIGLEC10 (Met571-Gln697).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
SIGLEC10,Siglec-10,Sialic acid-binding Ig-like lectin 10,Siglec-like protein 2,SLG2
Purification
Purified by antigen affinity column.
Accession
Q96LC7
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Sonocatalytic oncolysis microbiota curb intrinsic microbiota lactate metabolism and blockade CD24-Siglec10 immune escape to revitalize immunological surveillance., PMID:38878482
Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer., PMID:38652971
Proinflammatory polarization strongly reduces human macrophage in vitro phagocytosis of tumor cells in response to CD47 blockade., PMID:38593339
Checkpoint CD24 function on tumor and immunotherapy., PMID:38487533
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions., PMID:38279998
RARγ promotes the invasion and metastasis of thyroid carcinoma by activating the JAK1-STAT3-CD24/MMPs axis., PMID:37897947
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy., PMID:37846296
The ligand interactions of B cell Siglecs are involved in the prevention of autoimmunity to sialylated self-antigens and in the quality control of signaling-competent B cells., PMID:37504378
New hope for tumor immunotherapy: the macrophage-related "do not eat me" signaling pathway., PMID:37484024
The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia., PMID:37424400
Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway., PMID:36866919
Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation., PMID:36736908
Single-cell RNA sequencing identifies precise tolerogenic cellular and molecular pathways induced by depigmented-polymerized grass pollen allergen extract., PMID:36649758
CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma., PMID:35625912
SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma., PMID:35317832
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology., PMID:35012610
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma., PMID:34112250
CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function., PMID:33658999
A Guillain-Barré syndrome-associated SIGLEC10 rare variant impairs its recognition of gangliosides., PMID:33223341
Expression of Siglec-1, -3, -5 and -10 in porcine cDC1 and cDC2 subsets from blood, spleen and lymph nodes and functional capabilities of these cells., PMID:32234314
Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression., PMID:31534365
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy., PMID:31367043
CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function., PMID:29997173
Molecular characterization of porcine Siglec-10 and analysis of its expression in blood and tissues., PMID:25280627
SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders., PMID:24859880
Immune regulation by CD52-expressing CD4 T cells., PMID:23934027
Role of inhibitory BCR co-receptors in immunity., PMID:22394175
Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction., PMID:21478876
CD24 and Siglec-10 selectively repress tissue damage-induced immune responses., PMID:19264983
Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells., PMID:16677248
Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters., PMID:11579105
Cloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells., PMID:11358961
Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor., PMID:11284738
For research use only. Not for human or drug use.
